R. Meazza, B. Azzarone, and A. M. Orengo, Role of common-g chain cytokines in NK cell development and function: perspectives for immunotherapy, J Biomed Biotechnol, p.861920, 2011.

B. Carnemolla, L. Borsi, and E. Balza, Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix, Blood, vol.99, pp.1659-65, 2002.

R. N. Schwartz, L. Stover, and J. Dutcher, Managing toxicities of high-dose interleukin-2, Oncology, vol.16, pp.11-20, 2002.

C. Halin, S. Rondini, and F. Nilsson, Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature, Nat Biotechnol, vol.20, pp.264-273, 2002.

N. Pasche and D. Neri, Immunocytokines: a novel class of potent armed antibodies, Drug Discov Today, vol.17, pp.583-90, 2012.

R. E. Kontermann, Antibody-cytokine fusion proteins, Arch Biochem Biophys, vol.526, pp.194-205, 2012.

M. Johannsen, G. Spitaleri, and G. Curigliano, The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma, Eur J Cancer, vol.46, pp.2926-2961, 2010.

A. L. Gilman, M. F. Ozkaynak, and K. K. Matthay, Phase I study of ch14.18 with granulocytemacrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group, J Clin Oncol, vol.27, pp.85-91, 2009.

R. Baluna, J. Rizo, and B. E. Gordon, Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome, Proc Natl Acad Sci, vol.96, pp.3957-62, 1999.

W. Munger, S. Q. Dejoy, R. Jeyaseelan, and . Sr, Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2, Cell Immunol, vol.165, pp.289-93, 1995.

J. C. Steel, T. A. Waldmann, and J. C. Morris, Interleukin-15 biology and its therapeutic implications in cancer, Trends Pharmacol Sci, vol.33, pp.35-41, 2012.

J. G. Giri, D. M. Anderson, and S. Kumaki, IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2, J Leukoc Biol, vol.57, pp.763-769, 1995.

D. M. Anderson, S. Kumaki, and M. Ahdieh, Functional characterization of the human interleukin-15 receptor a chain and close linkage of IL15RA and IL2RA genes, J Biol Chem, vol.270, pp.29862-29871, 1995.

J. G. Giri, S. Kumaki, and M. Ahdieh, Identification and cloning of a novel IL-15 binding protein that is structurally related to the a chain of the IL-2 receptor, EMBO J, vol.14, pp.3654-63, 1995.

J. Marks-konczalik, S. Dubois, and J. M. Losi, IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice, Proc Natl Acad Sci, vol.97, pp.11445-50, 2000.

T. A. Waldmann, S. Dubois, and Y. Tagaya, Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy, Immunity, vol.14, pp.105-115, 2001.

C. Berger, M. Berger, and R. C. Hackman, Safety and immunologic effects of IL-15 administration in nonhuman primates, Blood, vol.114, pp.2417-2443, 2009.

M. K. Kennedy, M. Glaccum, and S. N. Brown, Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice, J Exp Med, vol.191, pp.771-80, 2000.

J. P. Lodolce, P. R. Burkett, and D. L. Boone, T cellindependent interleukin 15Ra signals are required for bystander proliferation, J Exp Med, vol.194, pp.1187-94, 2001.

X. C. Li, G. Demirci, and S. Ferrari-lacraz, IL-15 and IL-2: a matter of life and death for T cells in vivo, Nat Med, vol.7, pp.114-132, 2001.

S. Dubois, J. Mariner, and T. A. Waldmann, IL-15Ra recycles and presents IL-15 in trans to neighboring cells, Immunity, vol.17, pp.537-584, 2002.

P. R. Burkett, R. Koka, and M. Chien, Coordinate expression and trans presentation of interleukin (IL)215Ra and IL-15 supports natural killer cell and memory CD81 T cell homeostasis, J Exp Med, vol.200, pp.825-859, 2004.

E. Mortier, R. Advincula, and L. Kim, Macrophage-and dendritic-cell-derived interleukin-15 receptor a supports homeostasis of distinct CD81 T cell subsets, Immunity, vol.31, pp.811-833, 2009.

E. Mortier, J. Bernard, and A. Plet, Natural, proteolytic release of a soluble form of human IL-15 receptor a-chain that behaves as a specific, high affinity IL-15 antagonist, J Immunol, vol.173, pp.1681-1689, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-02437358

S. Dubois, H. J. Patel, and M. Zhang, Preassociation of IL-15 with IL-15R a-IgG1-Fc enhances its activity on proliferation of NK and CD81/CD44 high T cells and its antitumor action, J Immunol, vol.180, pp.2099-106, 2008.

M. Epardaud, K. G. Elpek, and M. P. Rubinstein, Interleukin-15/interleukin-15R a complexes promote destruction of established tumors by reviving tumor-resident CD81 T cells, Cancer Res, vol.68, pp.2972-83, 2008.

T. A. Stoklasek, K. S. Schluns, and L. Lefrançois, Combined IL-15/IL-15Ra immunotherapy maximizes IL-15 activity in vivo, J Immunol, vol.177, pp.6072-80, 2006.

E. Mortier, A. Qu-em-ener, and P. Vusio, Soluble interleukin-15 receptor a (IL-15R a)-sushi as a selective and potent agonist of IL-15 action through IL-15R b/g. Hyperagonist IL-15 3 IL-15R a fusion proteins, J Biol Chem, vol.281, pp.1612-1631, 2006.

G. Bouchaud, L. Garrigue-antar, S. E. , and V. , The exon-3-encoded domain of IL-15ra contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ra, J Mol Biol, vol.382, pp.1-12, 2008.

N. D. Huntington, N. Legrand, and N. L. Alves, IL-15 trans-presentation promotes human NK cell development and differentiation in vivo, J Exp Med, vol.206, pp.25-34, 2009.

A. Bessard, . Sol-e-v, and G. Bouchaud, High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor a fusion protein, in metastatic melanoma and colorectal cancer, Mol Cancer Ther, vol.8, pp.2736-2781, 2009.

L. D. Cahan, R. F. Irie, and R. Singh, Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2, Proc Natl Acad Sci, vol.79, pp.7629-7662, 1982.

N. Yuki, M. Yamada, and Y. Tagawa, Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy, J Neurol Sci, vol.149, pp.127-157, 1997.

L. Svennerholm, K. Bostr?-om, and B. Jungbjer, Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years, J Neurochem, vol.63, pp.1802-1813, 1994.

S. Birkl-e, G. Zeng, and L. Gao, Role of tumorassociated gangliosides in cancer progression, Biochimie, vol.85, pp.455-63, 2003.

B. M. Mueller, C. A. Romerdahl, and S. D. Gillies, Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody, J Immunol, vol.144, pp.1382-1388, 1990.

M. Imai, C. Landen, and R. Ohta, Complementmediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer, Cancer Res, vol.65, pp.10562-10570, 2005.

M. A. Cheever, J. P. Allison, and A. S. Ferris, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research, Clin Cancer Res, vol.15, pp.5323-5360, 2009.

R. Handgretinger, K. Anderson, and P. Lang, A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma, Eur J Cancer, vol.31, pp.261-268, 1995.

N. Alvarez-rueda, S. Leprieur, and B. Cl-emenceau, Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen, Clin Cancer Res, vol.13, pp.5613-5620, 2007.

T. Hori, T. Uchiyama, and M. Tsudo, Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus, Blood, vol.70, pp.1069-72, 1987.

Y. Nakamura, S. M. Russell, and S. A. Mess, Heterodimerization of the IL-2 receptor b-and g-chain cytoplasmic domains is required for signalling, Nature, vol.369, pp.330-333, 1994.

H. Perdreau, E. Mortier, and G. Bouchaud, Different dynamics of IL-15R activation following IL-15 cis-or trans-presentation, Eur Cytokine Netw, vol.21, pp.297-307, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-02437096

K. Kendra, J. Gan, and M. Ricci, Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice, Cancer Immunol Immunother, vol.48, pp.219-248, 1999.

R. A. Clynes, T. L. Towers, and L. G. Presta, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat Med, vol.6, pp.443-449, 2000.

F. J. Hernandez-ilizaliturri, V. Jupudy, and J. Ostberg, Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model, Clin Cancer Res, vol.9, pp.5866-73, 2003.

P. Bruhns, Properties of mouse and human IgG receptors and their contribution to disease models, Blood, vol.119, pp.5640-5649, 2012.

J. Eisenman, M. Ahdieh, and C. Beers, Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity, Cytokine, vol.20, pp.121-130, 2002.

J. Rowley, A. Monie, and C. Hung, Inhibition of tumor growth by NK1.11 cells and CD81 T cells activated by IL-15 through receptor b/ common g signaling in trans, J Immunol, vol.181, pp.8237-8284, 2008.

V. Kermer, V. Baum, and N. Hornig, An antibody fusion protein for cancer immunotherapy mimicking IL-15 transpresentation at the tumor site, Mol Cancer Ther, vol.11, pp.1279-88, 2012.